Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 0.67 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205641 | 0.83 | PIM1 (0.71) | PIM1PIM2PIM3 | |
| SCHEMBL4208072 | 0.78 | PARP1 (0.57) | PIM1PIM2MAPTEGFRALDH1A1 | |
| SCHEMBL29839746 | 0.74 | PARP1 (0.57) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL2257236 | 0.74 | PARP1 (0.57) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL11537464 | 0.72 | PARP1 (0.55) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL13698355 | 0.71 | EGFR (0.47) | MAPTEGFRALDH1A1SMN1; SMN2HTT | |
| SCHEMBL7428429 | 0.71 | PARP1 (0.54) | MAPTALDH1A1SMN1; SMN2LMNAPARP1 | |
| SCHEMBL11118149 | 0.70 | SMN1; SMN2 (0.50) | MAPTEGFRALDH1A1SMN1; SMN2HTT | |
| SCHEMBL525453 | 0.70 | PARP1 (0.50) | MAPTALDH1A1SMN1; SMN2PARP1TNKS | |
| SCHEMBL7216819 | 0.68 | EGFR (0.61) | MAPTEGFRALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885MAPT 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.